Marc Schwabish BS, PhD

Marc Schwabish has a diverse background spanning Biopharma, Finance, Consulting, and Science. He was previously Head of US Pharma Business Development and Licensing at Bayer. He worked across Bayer’s therapeutic areas, focusing on late stage development opportunities, commercialized assets, and innovative partnerships. Prior to Bayer, Marc had both Business Development and Alliance Management responsibilities at Eisai. His deal experience at Eisai covered a range of diseases and stages of assets — from early research technologies through commercialized therapeutics. Marc previously worked in Healthcare Investment Banking at RBS (Leverage Finance and M&A), Pharma Strategy Consulting at Leerink Swann (now Navigant), and other Pharma/Biotech companies (R&D and Product Management). He has closed over 25 transactions across Anti-Infectives, Cardiology, GI, Metabolism, Neurology, Oncology, Thrombosis, and Women’s Healthcare. Dr. Schwabish holds a Ph.D. in Biochemistry and Molecular Pharmacology from Harvard and a B.S. in Biology from Cornell.